Protection from Reperfusion Injury with Intracoronary N-Acetylcysteine in Patients with STEMI Undergoing Primary Percutaneous Coronary Intervention in a Cardiac Tertiary Center
Background Evidence suggests that oxidative stress plays a principal role in myocardial damage following ischemia/reperfusion events. Recent studies have shown that the antioxidant properties of N-acetylcysteine (NAC) may have cardioprotective effects in high doses, but—to the best of our knowledge—few studies have assessed this. Objectives Our objective was to investigate the impact of high-dose NAC on ischemia/reperfusion injury. Methods We conducted a randomized double-blind placebo-controlled trial in which 100 consecutive patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention (PCI) were randomly assigned to the case group (high-dose NAC 100 mg/kg bolus followed by intracoronary NAC 480 mg during PCI then intravenous NAC 10 mg/kg for 12 h) or the control group (5% dextrose). We measured differences in peak creatine kinase-myocardial band (CK-MB) concentration, highly sensitive troponin T (hs-TnT), thrombolysis in myocardial infarction (TIMI) flow, myocardial blush grade (MBG), and corrected thrombolysis in myocardial infarction frame count (cTFC). Results The peak CK-MB level was comparable between the two groups (P = 0.327), but patients receiving high-dose NAC demonstrated a significantly larger reduction in hs-TnT (P = 0.02). In total, 94% of the NAC group achieved TIMI flow grade 3 versus 80% of the control group (P = 0.03). No significant differences were observed between the two groups in terms of changes in the cTFC and MBG. Conclusions In this study, NAC improved myocardial reperfusion markers and coronary blood flow, as revealed by differences in peak hs-TnT and TIMI flow grade 3 levels, respectively. Further studies with large samples are warranted to elucidate the role of NAC in this population. ClinicalTrials.gov identifier: NCT01741207, and the Iranian Registry of Clinical Trials (IRCT; http://irct.ir) registration number: IRCT201301048698N8..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
American journal of cardiovascular drugs - 18(2018), 3 vom: 10. Jan., Seite 213-221 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nozari, Younes [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| doi: |
10.1007/s40256-017-0258-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR03295302X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR03295302X | ||
| 003 | DE-627 | ||
| 005 | 20230519104711.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40256-017-0258-8 |2 doi | |
| 035 | |a (DE-627)SPR03295302X | ||
| 035 | |a (SPR)s40256-017-0258-8-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 100 | 1 | |a Nozari, Younes |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Protection from Reperfusion Injury with Intracoronary N-Acetylcysteine in Patients with STEMI Undergoing Primary Percutaneous Coronary Intervention in a Cardiac Tertiary Center |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background Evidence suggests that oxidative stress plays a principal role in myocardial damage following ischemia/reperfusion events. Recent studies have shown that the antioxidant properties of N-acetylcysteine (NAC) may have cardioprotective effects in high doses, but—to the best of our knowledge—few studies have assessed this. Objectives Our objective was to investigate the impact of high-dose NAC on ischemia/reperfusion injury. Methods We conducted a randomized double-blind placebo-controlled trial in which 100 consecutive patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention (PCI) were randomly assigned to the case group (high-dose NAC 100 mg/kg bolus followed by intracoronary NAC 480 mg during PCI then intravenous NAC 10 mg/kg for 12 h) or the control group (5% dextrose). We measured differences in peak creatine kinase-myocardial band (CK-MB) concentration, highly sensitive troponin T (hs-TnT), thrombolysis in myocardial infarction (TIMI) flow, myocardial blush grade (MBG), and corrected thrombolysis in myocardial infarction frame count (cTFC). Results The peak CK-MB level was comparable between the two groups (P = 0.327), but patients receiving high-dose NAC demonstrated a significantly larger reduction in hs-TnT (P = 0.02). In total, 94% of the NAC group achieved TIMI flow grade 3 versus 80% of the control group (P = 0.03). No significant differences were observed between the two groups in terms of changes in the cTFC and MBG. Conclusions In this study, NAC improved myocardial reperfusion markers and coronary blood flow, as revealed by differences in peak hs-TnT and TIMI flow grade 3 levels, respectively. Further studies with large samples are warranted to elucidate the role of NAC in this population. ClinicalTrials.gov identifier: NCT01741207, and the Iranian Registry of Clinical Trials (IRCT; http://irct.ir) registration number: IRCT201301048698N8. | ||
| 700 | 1 | |a Eshraghi, Azadeh |e verfasserin |4 aut | |
| 700 | 1 | |a Talasaz, Azita Hajhossein |e verfasserin |4 aut | |
| 700 | 1 | |a Bahremand, Mostafa |e verfasserin |4 aut | |
| 700 | 1 | |a Salamzadeh, Jamshid |e verfasserin |4 aut | |
| 700 | 1 | |a Salarifar, Mojtaba |e verfasserin |4 aut | |
| 700 | 1 | |a Pourhosseini, Hamidreza |e verfasserin |4 aut | |
| 700 | 1 | |a Jalali, Arash |e verfasserin |4 aut | |
| 700 | 1 | |a Mortazavi, Seyedeh Hamideh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of cardiovascular drugs |d Cham : Springer, 2001 |g 18(2018), 3 vom: 10. Jan., Seite 213-221 |w (DE-627)SPR032943881 |w (DE-600)2043647-6 |x 1179-187X |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2018 |g number:3 |g day:10 |g month:01 |g pages:213-221 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s40256-017-0258-8 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2018 |e 3 |b 10 |c 01 |h 213-221 | ||